Understanding Cod Liver Oil: Nutrient Profile and Historical Use

Cod liver oil has been used for centuries as a traditional remedy for joint pain, rickets, and general immune support. The oil is extracted from the liver of Atlantic cod (Gadus morhua) and other related species. Its distinctive nutrient density sets it apart from most other fish oils: one tablespoon (about 15 mL) provides approximately 4 080 international units (IU) of vitamin A, 1 360 IU of vitamin D, and roughly 2.7 grams of omega-3 fatty acids, of which about 1.1 grams is eicosapentaenoic acid (EPA) and 0.8 grams is docosahexaenoic acid (DHA). These levels of vitamins A and D are far higher than what is found in standard fish-body oils, giving cod liver oil a unique therapeutic profile but also a narrower safety margin.

Historically, cod liver oil was a staple in Northern European and North American households during winter months when sunlight was scarce. The vitamin D content effectively prevented rickets in children, while the vitamin A supported immune function and vision. Today, the supplement is marketed primarily for its omega-3 content, but the presence of preformed retinol (vitamin A) remains a key distinction. For individuals with diabetes, who often have elevated baseline inflammation and dyslipidemia, the combination of EPA, DHA, and fat-soluble vitamins raises both potential benefits and risks that warrant careful examination.

Diabetes and Cardiovascular Disease: The Overlapping Risk Factors

Diabetes mellitus is inherently linked to accelerated cardiovascular disease (CVD). Chronic hyperglycemia drives oxidative stress, promotes advanced glycation end-products (AGEs), and impairs endothelial nitric oxide availability. These pathways contribute to a pro-inflammatory, pro-thrombotic state that manifests clinically as a two- to four-fold increase in the risk of myocardial infarction and stroke compared with individuals without diabetes. Even in well-controlled diabetes, residual lipid abnormalities often persist: elevated triglycerides, reduced high-density lipoprotein (HDL) cholesterol, and a predominance of small, dense low-density lipoprotein (LDL) particles that are particularly atherogenic.

Beyond dyslipidemia, diabetes frequently coexists with hypertension, obesity, and insulin resistance, each of which independently amplifies CVD risk. The concept of "diabetic cardiomyopathy" further underscores the direct effect of metabolic derangement on heart muscle structure and function. Given this complex interplay, adjunctive interventions that target inflammation, blood lipids, and vascular reactivity are especially appealing. Cod liver oil, with its omega-3 load, fits squarely into this strategy. However, the evidence for a meaningful reduction in hard cardiovascular endpoints in a diabetic population remains a matter of active debate.

The Science Behind Omega-3s and Cardiometabolic Health

Anti-inflammatory Pathways

EPA and DHA are precursors to specialized pro-resolving mediators (SPMs) called resolvins, protectins, and maresins. These molecules actively resolve inflammation rather than simply suppressing it. In diabetic patients, chronic low-grade inflammation marked by elevated C-reactive protein (CRP), interleukin-6, and tumor necrosis factor-alpha is a consistent finding. Omega-3 fatty acids incorporate into cell membrane phospholipids, displace arachidonic acid, and reduce the production of pro-inflammatory eicosanoids. Through these actions, cod liver oil may help lower systemic inflammation, which in turn could reduce atherosclerotic plaque progression and stabilize existing lesions.

Effects on Lipid Metabolism

The most well-documented effect of omega-3 supplementation is a dose-dependent reduction in serum triglycerides. EPA and DHA inhibit hepatic very-low-density lipoprotein (VLDL) secretion and enhance triglyceride clearance via increased lipoprotein lipase activity. Typical reductions of 20 % to 30 % can be expected with daily intakes of 2 to 4 grams of EPA plus DHA. Since hypertriglyceridemia is a common feature of diabetic dyslipidemia, this effect is particularly relevant. However, cod liver oil generally provides lower total omega-3 doses (about 2.5 to 3 grams per tablespoon) than concentrated prescription formulations. Modest increases in HDL and conversion of small, dense LDL to larger, more buoyant particles are additional benefits, although the magnitude of change is smaller than that seen with fibrates or high-dose omega-3 therapy.

Blood Pressure and Vascular Function

EPA and DHA enhance endothelial function by increasing nitric oxide production and reducing oxidative stress. Meta-analyses of randomized trials have estimated that omega-3 supplementation lowers systolic blood pressure by approximately 2 to 4 mmHg and diastolic pressure by 1 to 2 mmHg in normotensive individuals, with more pronounced effects in hypertensive or older populations. For a diabetic patient with borderline hypertension, this modest reduction could contribute to overall cardiovascular risk reduction. Improved arterial compliance and reduced pulse wave velocity have also been observed, suggesting direct benefits on vascular aging.

Glycemic Control and Insulin Sensitivity

Evidence linking omega-3 intake to improved glycemic control is less consistent. Some studies report small improvements in HbA1c and fasting glucose, while others show neutral or even slight increases in fasting glucose, especially at very high doses. The net effect in diabetic populations appears to be neutral for most patients. Importantly, the triglyceride-lowering and anti-inflammatory benefits of cod liver oil likely outweigh any marginal effect on glucose in the context of overall cardiovascular risk. Patients with diabetes should not expect significant improvements in blood sugar control from cod liver oil alone and should continue their prescribed hypoglycemic medications.

Clinical Evidence: Cod Liver Oil and Diabetes Outcomes

Landmark Studies and Systematic Reviews

The most robust evidence for omega-3 therapy in diabetes comes from large randomized trials and meta-analyses. The REDUCE-IT trial (2019) demonstrated a 25 % reduction in major adverse cardiovascular events with high-dose icosapent ethyl (purified EPA) in patients with established CVD or diabetes and elevated triglycerides. However, this study used a purified ethyl-ester formulation of EPA alone, not cod liver oil, and the dose was 4 grams per day, far exceeding what cod liver oil provides. The VITAL trial (2018) showed a non-significant trend toward cardiovascular risk reduction with 1 gram per day of fish oil (EPA plus DHA) in a general population without diabetes, but a pre-specified subgroup analysis suggested greater benefit in those with diabetes or at high risk. These data are encouraging but do not prove that the lower doses in cod liver oil produce comparable effects.

Several smaller randomized trials have specifically examined cod liver oil in type 2 diabetes. A 12-week study from Norway found that 10 mL of cod liver oil daily reduced triglycerides by 22 % and elevated HDL slightly compared with placebo. A separate trial reported improvements in von Willebrand factor and other markers of endothelial injury, though no effect on blood pressure or glucose was observed. Systematic reviews pooling these and similar studies conclude that omega-3 supplementation leads to a moderate reduction in triglycerides and a small increase in HDL, but evidence for prevention of hard outcomes like heart attack or stroke specifically with cod liver oil in diabetes is limited. Most guidelines recommend fish oil supplementation for triglyceride reduction but stop short of endorsing it as a primary preventive therapy for cardiovascular events in diabetic patients.

Mixed Results and Sources of Heterogeneity

The inconsistency in trial outcomes can be attributed to several factors. First, baseline dietary omega-3 intake varies widely among study populations; individuals already consuming two or more servings of fatty fish per week are unlikely to see additional benefit. Second, the dose and duration of supplementation matter. Short trials of three to six months may capture lipid changes but are too brief to assess event rates. Third, many trials of omega-3s have been conducted in patients already receiving optimal statin, antihypertensive, and antiplatelet therapy, which may attenuate the relative benefit. Fourth, cod liver oil differs from other fish oils in its vitamin content; high vitamin A levels may offset some omega-3 benefits by promoting oxidative stress in certain contexts. For these reasons, extrapolating from general fish oil data to cod liver oil specifically requires caution.

Traditional Cod Liver Oil vs. Purified Omega-3 Supplements

Cod liver oil is a whole-food supplement, meaning it retains the natural balance of EPA, DHA, vitamins A and D, and other minor fatty acids. Purified omega-3 concentrates (triacylglycerol or ethyl-ester forms) remove most of the vitamins and concentrate EPA and DHA to higher levels. For patients who need triglyceride reduction of 30 % or more, a concentrated prescription omega-3 may be more effective than cod liver oil. Conversely, patients seeking a broad-spectrum supplement that also provides vitamin D (for bone health and immune function) and vitamin A (for vision and skin) may find cod liver oil appealing as a combined product. The choice should be individualized based on the patient's specific metabolic profile, medication list, and dietary patterns.

Potential Cardiovascular Benefits Specific to Diabetes

Triglyceride Reduction

As noted, this is the strongest and most reproducible benefit. For a person with diabetes and fasting triglycerides above 200 mg/dL, adding 1 to 2 tablespoons of cod liver oil daily could lower triglycerides by 15 % to 25 %. This reduction is clinically meaningful because every 1 mmol/L (about 89 mg/dL) reduction in triglycerides is associated with a 10 % lower risk of cardiovascular events in patients with hypertriglyceridemia. The effect is additive to statins and fibrates, allowing some patients to avoid additional medication.

Inflammation and Endothelial Health

Lowering CRP and other inflammatory markers through EPA/DHA intake may reduce the propagation of atherosclerotic plaques. Diabetic patients have impaired endothelium-dependent vasodilation, and some studies show that cod liver oil can restore part of this responsiveness. Improved brachial artery flow-mediated dilation, a surrogate marker for endothelial function, has been reported in both diabetic and non-diabetic volunteers after four to eight weeks of cod liver oil supplementation.

Potential Neuroprotective and Retinal Effects

DHA is a structural component of retinal and neuronal membranes. Diabetic retinopathy and peripheral neuropathy are microvascular complications driven by inflammatory and oxidative injury. Some evidence suggests that DHA enrichment in the retina and nerve tissues may slow the progression of these complications. Specific trials of cod liver oil for retinopathy are sparse, but the nutrient overlap with retinal health is plausible. For patients with type 2 diabetes and early retinopathy, ensuring adequate DHA intake through either fish consumption or supplementation may be a reasonable low-risk strategy, provided vitamin A levels remain within safe limits.

Platelet Aggregation and Thrombosis

EPA and DHA have mild antiplatelet effects through inhibition of thromboxane A2 and enhancement of prostacyclin production. This can theoretically reduce the risk of thrombotic events such as heart attack and ischemic stroke. In practice, the clinical significance of this effect at cod liver oil doses is modest. However, in a diabetic patient already on aspirin or clopidogrel, the addition of cod liver oil may amplify bleeding risk. Healthcare providers should be aware of this potential interaction, particularly in individuals with a history of gastrointestinal bleeding or hemorrhagic stroke.

Important Precautions and Risks

Vitamin A and D Toxicity

The most serious risk associated with cod liver oil is hypervitaminosis A and D. Vitamin A (retinol) accumulates in the liver, and chronic intake exceeding 10 000 IU per day can lead to toxicity symptoms such as dry skin, bone pain, hepatomegaly, and increased intracranial pressure. Vitamin D toxicity is less common but can cause hypercalcemia, nephrolithiasis, and renal damage. One tablespoon of cod liver oil provides approximately 4 080 IU of vitamin A and 1 360 IU of vitamin D. For many adults, this falls within safe limits, but individuals who consume other fortified foods or take separate vitamin A or D supplements may exceed the tolerable upper intake levels. Patients with diabetes and fatty liver disease may be more susceptible to vitamin A hepatotoxicity. The safest approach is to measure baseline serum retinol and 25-hydroxyvitamin D levels before starting supplementation and to recheck periodically.

Anticoagulant Effects and Drug Interactions

Cod liver oil can prolong bleeding time. In patients taking warfarin, heparin, direct oral anticoagulants, or high-dose aspirin, the combination may increase the risk of bruising or major bleeding. Although the effect is generally mild, case reports of epistaxis, hematuria, and intracranial hemorrhage exist. The international normalized ratio (INR) should be monitored closely when starting cod liver oil in patients on warfarin. For those on newer anticoagulants, a cautious approach is warranted, and patients should be advised to report any unusual bleeding promptly.

Contamination and Oxidation Concerns

Cod liver oil, like all fish-derived products, can carry environmental contaminants such as polychlorinated biphenyls (PCBs), dioxins, and heavy metals (mercury, lead, cadmium). Reputable manufacturers employ molecular distillation and third-party testing to ensure purity and freshness. Oxidation is another issue: omega-3s are polyunsaturated and prone to rancidity, which creates lipid peroxides that may actually promote oxidative stress. Consumers should look for products that list a peroxide value and a total oxidation value (TOTOX) on the certificate of analysis, or at minimum choose oils that are kept in opaque, nitrogen-flushed bottles to minimize oxidation.

Dosage and Quality Considerations

Standard doses range from one teaspoon (5 mL) to two tablespoons (30 mL) daily. For most diabetic patients, 5 to 10 mL per day is sufficient to obtain omega-3 benefits while keeping vitamin A intake at a reasonable level. Higher doses should only be used under medical supervision and for a defined clinical goal, such as severe hypertriglyceridemia. Choosing a brand that participates in the International Fish Oil Standards (IFOS) program or has been verified by ConsumerLab or USP provides assurance of potency and purity.

Practical Recommendations for Integrating Cod Liver Oil into Diabetes Management

Before starting cod liver oil, patients should have a comprehensive assessment that includes a lipid panel, liver function tests, and vitamin A and D levels. Health care providers should review the patient's full medication list for potential interactions. If baseline triglycerides are elevated (≥200 mg/dL) and lifestyle measures have been exhausted, a trial of cod liver oil at 5 to 10 mL per day for three months can be considered, followed by repeat lipid testing to evaluate response.

Patients should be counseled on proper storage: keep the oil in a dark, cool cabinet away from heat and light, and never use a supplement that smells fishy or rancid. Liquid forms are generally absorbed better than capsules, but capsules offer convenience and easier dose calibration. Neither form should be taken within two hours of other fat-soluble vitamin supplements to avoid excessive cumulative intake.

For those who cannot tolerate the taste or gastric effects, refrigeration or taking the oil with a meal often reduces discomfort. Diabetic patients with concurrent pancreatitis or cholecystitis should use cod liver oil with caution due to its high-fat content, which could trigger symptoms in susceptible individuals.

Ultimately, cod liver oil should be viewed as a complementary strategy, not a replacement for established cardiovascular therapies. Statins, antihypertensives, antiplatelet agents, and lifestyle modifications (diet, exercise, glycemic control) remain the cornerstones of risk reduction. The best evidence for omega-3 benefit in diabetes comes from formulations that deliver at least 2 grams per day of EPA plus DHA, a dose that cod liver oil can approach only at relatively high volumes (two tablespoons or more). Patients who are unwilling or unable to consume that amount may derive modest lipid benefits from lower doses but should not expect dramatic reductions in cardiovascular events.

Conclusion

Cod liver oil offers a unique combination of omega-3 fatty acids and fat-soluble vitamins that may provide modest cardiovascular benefits for individuals with diabetes, particularly in lowering triglycerides and reducing systemic inflammation. However, the current evidence base is not robust enough to recommend cod liver oil as a primary intervention for preventing heart attack or stroke in this population. The supplement carries genuine risks related to vitamin A and D toxicity, bleeding interactions, and product quality variability. A personalized approach, guided by laboratory testing and clinical evaluation, is essential before incorporating cod liver oil into a diabetes management plan. For those who can use it safely, cod liver oil can be a useful adjunct to standard care, but it is not a substitute for proven pharmacological and lifestyle therapies. Further large-scale trials specifically testing cod liver oil against hard cardiovascular endpoints in diabetic patients are needed to clarify its role.